Where does the Clinical Relevance information come from ?
Information is essentially from Damoiseaux et al. 2019 (Ann Rheum Dis. 78:879-89) with updates and references cited as they become available.
What is the difference between Clinical Relevance first and second level information ?
The
first level should contain information on relevant follow-up testing in
the respective clinical context, the recommended follow-up tests should
be commercially available, and detailed test characteristics should not
be given because of potential geographic and jurisdictional
differences. Information based on case reports or small patient cohorts,
as well as information on possible follow-up testing that is only
available in specialized research laboratories, should only be provided
in the second level information. Thus, first level information is
extracted from the three main tables (Ann Rheum Dis. 78:879-89) while second level information is extracted from the three supplemental tables.
List of abbreviations:
Ago, argonaute protein; AIH, autoimmune hepatitis; AIM, autoimmune
myopathy; ALBIA, addressable laser-bead immuno-assay; AMA,
antimitochondrial antibodies; APS, antiphospholipid syndrome; CENP,
centromere-associated protein; Cep, centrosomal protein; CLIP, class
II-associated invariant chain peptide; DCA, dividing cell antigen; DFS,
dense fine speckled; DM, dermatomyositis; dsDNA, double stranded DNA;
EBV, Epstein-Barr virus; EEA, early endosome antigen; ELISA,
enzyme‐linked immunosorbent assay; ENA, extractable nuclear antigens;
GPA, granulomatosis with polyangiitis; GRASP, glutamate receptor
interacting protein-associated protein; GW, glycine (G) – tryptophan (W)
repeat; HCV, hepatitis C virus; Hedls, human enhancer of decapping
large subunit; HIV, human immunodeficiency virus; hUBF, human upstream
binding factor; IIFA, indirect immunofluorescence assay; INCENP, inner
centromere protein; KIF, kinesin family; LAP, lamin-associated
polypeptide; LBPA, lysobiphosphatidic acid; LBR, lamin B receptor;
LEDGF, lens epithelial derived growth factor; MCA, mitotic chromosomal
antigen; MCTD, mixed connective tissue disease; MKLP, mitotic
kinesin-like protein; MPP, M-phase phosphoprotein; MSA, mitotic spindle
apparatus; NMP, nuclear matrix protein; NOR, nucleolus organizer region;
NuMA, nuclear mitotic apparatus; NXP, nuclear matrix protein; PBC,
primary biliary cholangitis; PCM, pericentriolar material; PCNA,
proliferating cell nuclear antigen; PML, promyelocytic leukaemia;
PM/Scl, polymyositis-scleroderma; RA, rheumatoid arthritis; RibP,
ribosomal phosphoprotein; RNApol, RNA polymerase; RNP,
ribonucleoprotein; SARD, systemic autoimmune rheumatic diseases; SjS,
Sjögren’s syndrome; SLE, systemic lupus erythematosus; SMN, survival of
motor neuron; SRP, signal recognition protein; ssDNA, single stranded
deoxyribonucleic acid; SSc, systemic sclerosis; TIF, transcription
intermediary factor; Tpr, translocated promoter region; TRIM, tripartite
motif; tRNA, transfer ribonucleic acid; UCTD, undifferentiated
connective tissue disease.